Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP56 Sofosbuvir, velpatasvir and voxilaprevir
D10900 Sofosbuvir, velpatasvir and voxilaprevir <US>
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis C (HCV) Agents
Sofosbuvir/ Velpatasvir/ Voxilaprevir
D10900 Sofosbuvir, velpatasvir and voxilaprevir
Drug groups [BR:br08330]
Antiviral
DG03198 Anti-HCV agent
D10900 Sofosbuvir, velpatasvir and voxilaprevir
Drug classes [BR:br08332]
Antiviral
DG03198 Anti-HCV agent
D10900 Sofosbuvir, velpatasvir and voxilaprevir
Antimicrobials [BR:br08307]
Antivirals
Polyprotein cleavage inhibitor
HCV NS3/4A inhibitor
D10900 Sofosbuvir, velpatasvir and voxilaprevir <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10900
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10900
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10900
